# Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC

> **NCT04143191** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 158 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sorafenib
- **PROCEDURE:** Transarterial chemoembolization

## Key facts

- **NCT ID:** NCT04143191
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-15
- **Primary completion:** 2021-09-15
- **Final completion:** 2023-09-15
- **Target enrollment:** 158 (ESTIMATED)
- **Last updated:** 2020-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04143191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04143191, "Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04143191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*